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JOURNAL OF HEPATOLOGYImpact of subclinical hypothyroidism on the development of
non-alcoholic fatty liver disease: A prospective case-control studyTo the Editor:
We read with great interest the article by Chung et al. [1] show-
ing that subclinical hypothyroidism, even in the range of upper
normal thyroid stimulating hormone (TSH) levels, was closely
associated with non-alcoholic fatty liver disease (NAFLD) in a
dose-dependent manner. Their results indeed provided impor-
tant evidence, conﬁrming the close relationship between these
two diseases. However, as mentioned by the authors, the causal
relationship between hypothyroidism and NAFLD could not be
identiﬁed by their cross-sectional study.
Recently, we have performed a prospective case-control study
to evaluate the impact of subclinical hypothyroidism on the
development of NAFLD in a Chinese population. The study was
conducted among the employees of Zhenhai Reﬁning & Chemical
Company Ltd., Ningbo, China, since 2006. The study population
was described in detail in our previous studies [2,3]. A total of
327 subclinical hypothyroidism subjects were enrolled. Age, gen-
der, and body mass index (BMI) are three major factors that may
inﬂuence the development of NAFLD. To reduce the inﬂuence of
these variables, we randomly selected 327 age, gender, and BMI
matched euthyroid subjects as controls.
All the subjects were free of NAFLD at baseline, and did not
have a history of excessive alcohol consumption or liver disease.
Subclinical hypothyroidism was deﬁned as a TSH level of
4.5 mIU/L or greater, after excluding subjects with an abnormal
thyroxine level [4,5]. NAFLD was diagnosed based on the results
of abdominal ultrasonography, after exclusion of alcohol con-
sumption, viral, or autoimmune liver disease [6,7]. The develop-
ment of NAFLD was evaluated annually during follow-up by
ultrasound examination, using a Toshiba Nemio 20 sonographyJournal of Hepatology 2012machine with a 3.5-MHz probe (Toshiba, Tokyo, Japan). Ultra-
sound studies were carried out by experienced ultrasonogra-
phists who were blinded to the clinical and laboratory data.
A total of 63 subclinical hypothyroidism subjects and 35
euthyroid subjects developed NAFLD during a median follow-up
of 4.92 years. Compared to the euthyroid subjects, the incidence
of NAFLD for 1000 person-years of follow-up was signiﬁcantly
higher in the subjects with subclinical hypothyroidism (38.3 vs.
21.8; p <0.05).
Subclinical hypothyroidism subjects were further classiﬁed
into three subgroups according to their TSH levels: 4.5–
6.9 mIU/L (mild elevation), 7.0–9.9 mIU/L (moderate elevation),
and 10.0 mIU/L or greater (severe elevation). The incidence of
NAFLD showed an increased trend with increasing TSH levels.
The incidence of NAFLD per 1000 person-years of follow-up
was 21.8, 34.2, 48.3 and 52.5 for the euthyroid, mild, moderate
and severe elevation subgroup, respectively (p <0.05 for trend).
This observation indicated that subjects with higher baseline
TSH levels are more likely to develop NAFLD during the follow-
up period.
Cox proportional hazards regression analyses were used to
estimate hazard ratios for incident NAFLD for subclinical hypo-
thyroidism over the follow-up period. Our analysis showed that
subclinical hypothyroidism was a risk factor for the development
of NAFLD in the unadjusted model, the hazard ratio (95% CI) was
1.77 (1.17–2.67). The metabolic syndrome is a major mediating
variable for the studied relationship. Therefore, we further
adjusted the indicators of the metabolic syndrome in the Cox pro-
portional hazards regression analysis. Our result showed that the
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Letters to the Editor
remained signiﬁcant even after further adjustment for the indica-
tors of the metabolic syndrome, including waist circumference,
systolic blood pressure, diastolic blood pressure, triglyceride,
HDL cholesterol and fasting plasma glucose, the adjusted hazard
ratio (95% CI) was 2.21 (1.42–3.44). These results indicated that
subclinical hypothyroidism is an independent factor that predicts
the development of NAFLD.
A limitation of this study is that ultrasound examination is not
sensitive enough to detect mild steatosis. However, ultrasonogra-
phy is the most commonly used in epidemiological surveys of
NAFLD. Ultrasonography has the advantage of being non-inva-
sive, safe, widely available, and sensitivity for detecting hepatic
steatosis is acceptable. Another limitation is that the causal rela-
tionship between subclinical hypothyroidism and development
of NAFLD could not been drawn by this study. Further evidence
is needed to clarify this issue.
Taken together, our prospective case-control study provided
evidence that subclinical hypothyroidism is a signiﬁcant factor
associated with NAFLD development. This ﬁnding may have
important clinical implications for disease therapy and
prevention.
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Program (No. 2012CB524905).Regulatory T cell defects in a
To the Editor:
Peiseler et al. report that FOXP3pos regulatory T cells (Treg) in
adult patients with autoimmune hepatitis (AIH) are ‘‘fully func-
tional and not reduced in frequency’’ [1].
We wish to make a few comments.
Quoting previous literature on Tregs in AIH [2,3], the authors
state that most information has been obtained in paediatric cases.
We have published data on 47 adult patients with AIH type 1
conﬁrming the ﬁndings obtained in the paediatric setting and
reported that the frequency of CD4posCD25highFOXP3pos cells is
markedly reduced in AIH compared to healthy subjects, that this
decrease is more marked when the disease is more active and
that the numerical impairment is mirrored by the defective abil-
ity of Treg cells to control proliferation of CD4posCD25neg target
cells [4]. We have also shown that the decrease in Tregs is paral-
leled by a numerical impairment in natural killer T (NKT) cells [4],
a subset of cells with regulatory properties, suggesting that, con-
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dult autoimmune hepatitis
trary to what proposed by Peiseler et al., a broad immune-regula-
tory T cell defect is probably present in AIH.
The contrasting peripheral blood results between Peiseler
et al. and our study probably derive from methodological
differences. It is, however, difﬁcult to compare our methods with
those used in their paper, as they do not describe in detail their
methodology. The purity of their CD4posCD25high Treg is only
80–90%, and no data are provided to assess the efﬁciency of the
puriﬁcation protocol they have used (they refer to preliminary
results, but do not show them) or whether their puriﬁed cells
are CD127low. Moreover, in contrast to previous reports [2,3],
including ours [4], Peiseler et al. use a Treg/T-effector ratio of 1/
1 when assessing the suppressor function, while Tregs normally
represent some 4% of the total CD4+ lymphocyte population in
the human blood [5].
Concerning the immunohistochemistry data, Peiseler et al. say
that their results differ from ours [4], as, in contrast to us, they
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